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A B S T R A C T   
Background: The metabolic dietitian/nutritionist (hereafter ‘dietitian’) plays an essential role in the nutritional 
management of patients with phenylketonuria (PKU), including those on pegvaliase. Currently, more educational 
support and clinical experience is needed to ensure that dietitians are prepared to provide optimal nutritional 
management and counselling of pegvaliase-treated patients. 
Methods: Via a face-to-face data-review meeting, followed by a virtual consolidation meeting, a group of expert 
dietitians and one paediatrician discussed and developed a series of recommendations on the nutritional eval-
uation and management of patients receiving pegvaliase. The consensus group consisted of 10 PKU experts: six 
dietitians and one paediatrician from Europe and three dietitians from the US. One European and three US di-
etitians had experience with pegvaliase-treated patients. 
Results: The consensus group recommended that a physician, dietitian and nurse are part of the pegvaliase 
treatment team. Additionally, a psychologist/counsellor should be included if available. Practical proposals for 
the nutritional evaluation of pegvaliase-treated patients at baseline, during the induction and titration phases 
and for long-term maintenance were developed. The consensus group suggested assessment of blood Phe at least 
monthly or every 2 weeks in the event of low blood Phe (i.e., blood Phe <30 μmol/L). It may be appropriate to 
increase blood Phe monitoring when adjusting protein intake and/or pegvaliase dose. It was recommended that 
natural protein intake is increased by 10–20 g increments if blood Phe concentrations decrease to <240 μmol/L 
in patients who are not meeting the dietary reference intake for natural protein of 0.8 g/kg. It was proposed that 
with pegvaliase treatment blood Phe levels could be maintained <240 μmol/L but more evidence on the safety of 
achieving physiological blood Phe levels is necessary before any recommendation on the lower blood Phe target 
can be given. Finally, both patients and dietitians should have access to educational resources to optimally 
support patients receiving pegvaliase. 
Abbreviations: BMI, body mass index; DRI, dietary reference intake; DXA, dual-energy x-ray absorptiometry; EMA, European Medicines Agency; FDA, Food and 
Drug Administration; LBP, low blood phenylalanine; PAH, phenylalanine hydroxylase; PAL, PEGylated recombinant phenylalanine ammonia lyase; Phe, phenylal-
anine; PKU, phenylketonuria; QoL, quality of life. 
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Conclusion: This practical road map aims to provide initial recommendations for dietitians monitoring patients 
with PKU prescribed pegvaliase. Given that practical experience with pegvaliase is still limited, nutritional 
recommendations will require regular updating once more evidence is available and clinical experience evolves.   
1. Introduction 
Phenylketonuria (PKU) is a rare autosomal recessive disorder caused 
by deficiency in activity of the hepatic enzyme, phenylalanine hydrox-
ylase (PAH) [1]. Without treatment, it results in elevated blood and 
brain phenylalanine (Phe) concentrations, leading to neurocognitive 
and neuropsychological complications [1,2]. American and European 
guidelines recommend lifelong treatment and follow-up although their 
upper blood Phe targets vary (in patients aged ≥12 years ≤360 and 600 
μmol/L, respectively) [2,3]. Dietary restriction of Phe, maintaining 
blood Phe within treatment range, can prevent severe complications 
when initiated immediately after diagnosis, usually soon after birth as 
PKU is identified via newborn screening programmes [2,3]. However, 
dietary management poses a significant burden to patients with PKU, 
resulting in a progressive deterioration in dietary adherence and a 
subsequent increase in blood Phe concentrations [4,5]. Sapropterin 
dihydrochloride (sapropterin) was the first non-dietary pharmacological 
therapy for PKU [6,7]. Although effective in lowering blood Phe con-
centrations and increasing Phe tolerance, it is mainly used in conjunc-
tion with a Phe-restricted diet and in patients with residual PAH activity 
[8–10]. The treatment landscape of PKU has further expanded with the 
approval of pegvaliase, an enzyme substitute therapy consisting of a 
PEGylated recombinant phenylalanine ammonia lyase (PAL) isolated 
from the cyanobacterium Anabaena variabilis that converts Phe to 
ammonia and trans-cinnamic acid [11]. In May 2018, the Food and Drug 
Administration (FDA) approved the use of pegvaliase for the treatment 
of adult patients with PKU with blood Phe >600 μmol/L [12]. In May 
2019, the European Medicines Agency (EMA) approved pegvaliase for 
the treatment of PKU patients aged ≥16 years with blood Phe >600 
μmol/L [13]. Consensus recommendations for pegvaliase were devel-
oped in 2018 by US healthcare professionals who were involved in the 
clinical development programme [14]. These consensus recommenda-
tions defined that the treatment goal of pegvaliase is to provide lifelong 
reduction of blood Phe and to normalise diet while maintaining blood 
Phe below guideline recommended thresholds [14]. Given the central 
role of metabolic dietitians/nutritionists (hereafter ‘dietitian’) in the 
management of patients with PKU, this paper aims to develop a practical 
road map for dietitians who are managing patients with PKU treated 
with pegvaliase. These dietary recommendations are based on expert 
opinion and should have regular review when real-world evidence ac-
cumulates with evolving clinical pegvaliase experience. Therefore, these 
dietary recommendations are intended as a starting point for dietitians 
who are caring for patients with PKU on pegvaliase. 
2. Methods 
A group of experienced dietitians and one paediatrician (hereafter 
‘consensus group’) working with PKU attended a face-to-face data-re-
view meeting, followed by a virtual consolidation meeting, to discuss 
the nutritional management of PKU patients before and during treat-
ment with pegvaliase. 
At the time, the only European country which had experience with 
pegvaliase was Germany. Therefore, one German dietitian who was 
experienced in treating and managing patients on pegvaliase was 
included to bring the EU perspective on treatment with pegvaliase. The 
other six EU PKU experts, who did not have experience with pegvaliase, 
are internationally recognised for their experience in PKU and most of 
them are part of the European Nutritionist Group on PKU. Additionally, 
three US dietitians with proven long-term experience in PKU and in 
treating and managing diet for patients on pegvaliase joined the 
meeting. Both meetings aimed to use insights from these EU and US PKU 
experts to develop consensus on the nutritional evaluation before initi-
ation of pegvaliase and to develop recommendations for dietary ad-
justments during treatment with pegvaliase. 
2.1. Face-to-face dietitian meeting 
In November 2019, eight dietitians (six EU and two US dietitians) 
attended the face-to-face meeting. During the meeting, the pegvaliase 
clinical trial data and prescription labels were reviewed and topics 
concerning the nutritional management of PKU patients in the context of 
pegvaliase were discussed. Discussion was structured and guided by 
presentations with questions formulated by three of the expert di-
etitians. Detailed minutes of the meeting were taken and 17 draft rec-
ommendations were formulated. 
2.2. Virtual consolidation meeting 
Recommendations were developed in five areas of pegvaliase treat-
ment: the multidisciplinary team (2 statements), nutritional status 
evaluation and follow-up (4 statements), diet and protein intake (7 
statements), blood Phe target range (2 statements) and education (2 
statements). 
In March 2020, a secure online-platform was set up using the virtual 
engagement tool, Within3 (https://www.within3.com/), aiming to work 
towards consensus recommendations for the nutritional management of 
pegvaliase-treated patients. On the platform, the PKU experts could 
share their opinion on each statement and respond to each other's 
comments. Participants could log in as often as desired at any time 
during a 4-week commenting period. Except for two EU dietitians, all 
attendees of the face-to-face meeting participated in the virtual meeting. 
Additionally, one EU paediatrician and one US dietitian who were not 
present at the face-to-face meeting participated in the virtual platform 
discussion. 
2.3. Practice recommendations 
The practice recommendations and outcomes of the discussions from 
both meetings are described. Practice recommendations on the clinical 
approach for treating patients with pegvaliase were initiated by the 
dietitians with pegvaliase experience (three US and one EU dietitian) 
while the other experts considered each of these using their experience 
working with PKU within the EU to ensure good applicability in Euro-
pean centres. Although the statements are based on expert opinion and 
available literature only, they aim to give practical guidance to di-
etitians. These practice recommendations are minimum care re-
quirements and consider different hospital resources and infrastructure 
within the same or different countries. 
3. Results 
3.1. A multidisciplinary team to support patients with PKU on pegvaliase 
It is important to establish key members of the multidisciplinary 
team supporting patients on pegvaliase and to systematically collect 
data to measure the full impact of introducing pegvaliase as a treatment. 
The consensus group agreed that the core pegvaliase treatment team 
should consist of a physician, a dietitian and a nurse (either a registered 
nurse or a nurse practitioner). It also strongly recommended that a 
psychologist/counsellor should be an integral part of the core pegvaliase 





Proposed composition of the multidisciplinary team at centres treating PKU patients with pegvaliase.  
Specialty Responsibilities 
Consensus group recommendations about the composition of the multidisciplinary teams at centres treating PKU patients with pegvaliase  
Physician - Diagnosis and decisions on appropriate therapeutic approach, considering potential adverse events 
- Pegvaliase prescription 
- Patient assessment prior to receiving pegvaliase 
- Titration of pegvaliase dose and assessment of patient progress during follow-up clinic visits 
- Management of adverse reactions 
Dietitian/nutritionist - Key role in monitoring and assuring adequate nutritional status of patients 
- Detailed food pattern analysis pre- and post-pegvaliase 
- Nutrition re-education as a strategy to reduce the risk of lifestyle-related comorbidities 
- Assessment of nutritional intake 
- Interpretation of blood Phe results in conjunction with dietary evaluation 
- Assessment of patient progress during follow-up clinic visits 
- Contribute to decisions on appropriate therapeutic approach, based on individual (dietetic) patient status/needs 
- Point of contact for the patient in terms of blood Phe reporting and diet education 
Nurse - Education and practical support of patients on pegvaliase injections 
- Point of contact for the patient in terms of managing drug titration and side effects 
- In some countries, nurse practitioners can also prescribe medication and assess patient's progress during follow-up clinic visits 
- Underline the global advice given by the physician and dietitian regarding treatment adherence, administration and dietary management  
If resources are available, the following specialties should be included in the multidisciplinary team:  
Psychologist/counsellor (highly recommended) - Surveillance and follow-up on any neurocognitive/psychological deficits 
- Perform neurocognitive testing and quality of life assessments 
- Patient counselling and support 
- Monitor patient's fears and help manage their expectations 
Social worker - Assessing individual patients' socioeconomical needs and support system, and providing assistance in finding solutions in these areas 
- Advising and supporting patients in contacting the necessary service providers/agencies 
Home support worker - Home support with blood sampling, treatment, social challenges and pregnancy management 
- Can be any profession depending on availability, although a nurse would be able to provide education and support regarding injections and potential adverse events 
Coordinator - Administrative assistant as central point of contact for e.g., organising appointments 
- Especially valuable at treatment initiation to coordinate appointments with the multidisciplinary team 
Phe: phenylalanine, PKU: phenylketonuria. 
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treatment team emphasising the importance of assessing the neuro-
cognitive and psychological status of pegvaliase-treated patients, 
although it was recognised some clinics may not have access to these 
resources. Considering the challenges imposed by this new pharmaco-
logical treatment, a detailed analysis of the patient's expectations may 
justify the need for a psychologist/counsellor in the team. If resources 
are available, a social worker, home support worker and coordinator 
should be part of the multidisciplinary treatment team. Table 1 provides 
an overview of all specialists and their respective roles within the 
multidisciplinary team to ultimately ensure optimal and safe use of 
pegvaliase for the treatment of patients with PKU. 
3.2. Nutritional evaluation before and during pegvaliase 
3.2.1. Baseline 
The baseline nutritional status of patients before pegvaliase initia-
tion is necessary to evaluate treatment outcomes. In general, clinical 
evaluation and follow-up should be in agreement with the recommen-
dations of the European PKU guidelines [2]. The consensus group pro-
posed a standard of nutritional status assessments before the initiation of 
pegvaliase (Table 2). Regular assessment of blood Phe concentrations 
and anthropometric parameters is required to determine the efficacy of 
pegvaliase and evaluate the impact of dietary changes on the patient's 
anthropometrics, respectively. It is also recommended to extensively 
assess nutritional intake and food patterns (e.g., total protein intake, 
protein substitute intake, natural protein intake, quality of the protein 
source, number of meals each day) to determine the adequacy of protein 
and nutrient intake. Pre-pegvaliase, patients may typically fall into one 
of three categories: 1) the patient is not following a restricted diet and is 
meeting the dietary reference intake (DRI) for natural protein of 0.8 g/ 
kg, 2) the patient is following a Phe-restricted diet with an adequate 
amount of protein equivalent from protein substitutes to meet protein 
needs or 3) the patient is consuming an inadequate amount of protein 
equivalent from protein substitute and not eating sufficient natural 
protein. A food frequency questionnaire, as has been described by Viau 
et al. 2014 [15], combined with either 24-h dietary recall or 3-day food 
records is the usual method of assessing nutritional intake. Innovative 
methods for the assessment of dietary intake can also be explored, such 
as photographic meal diaries or filling out dietary information via a 
mobile application. Food neophobia questionnaires are useful to assist 
dietitians and/or psychologists/counsellors in assessing the patients' 
willingness/readiness and fears in changing their eating habits. While 
not validated in patients with PKU specifically, a modified version of the 
Food Neophobia Scale from Pliner et al. [16] has been previously used in 
a prospective controlled study to assess neophobia in patients with PKU 
[17,18]. As pegvaliase may change the patient's dietary regimen and 
result in decreased nutrient intake from non-natural sources, the 
biochemical micronutrient and amino acid status, including tyrosine, 
should be assessed. Although some EU dietitians commonly assess body 
composition of their adult PKU patients, this is not usually evaluated in 
US dietary practices. Therefore, analysis of body composition would be 
an optional requirement to initiate pegvaliase. Nevertheless, collecting 
data on body composition would aid metabolic teams in understanding 
the impact of dietary changes associated with pegvaliase treatment on 
PKU-associated comorbidities, such as obesity, metabolic syndrome, and 
Table 2 
Proposed assessments for nutritional status. Frequency of all assessments may be 
increased if there is a clinical reason for concern or according to the centre's 
current follow-up protocol.  












biomarker of blood 
Phe control 
- Monthly regular 
follow-up 
- Monthly regular 
follow-up 
- Every 2 weeks in 
case of LBP 
(blood Phe <30 
μmol/L) 
- Every 2 weeks in 
case of LBP 
(blood Phe <30 
μmol/L) 










- Weight, height 
and BMI 
- Up to once per 
month 






- Food frequency 
questionnaire 
(preferred) 
- Once per month - Every 6 months 
- 24-h recall records 
or 3-day food 
records 
- Food neophobia 
questionnaire 
(optional)  
Assessments for nutritional status evaluation strongly recommended by the 
consensus group  
Blood analysis (in 
addition to 
Phe) 
- Full amino acid 
profile, including 
tyrosine 




















• Folic acid 
• Vitamin B12 




• Selenium  




- Fat-free mass and 
body fat 
- Every 6 months 
or once yearly 
- Once yearly 







- DXA scan to 
exclude osteopenia 
and osteoporosis 
- Every 3–5 years - Every 3–5 years 
- Per EU PKU 
guidelines, this 
should be done 
based on identified  
Table 2 (continued ) 








risk, but not 
essential in routine 
follow-up [2] 
BMI: body mass index; DXA: dual-energy x-ray absorptiometry; LBP: low blood 
Phe, Phe: phenylalanine, PKU: phenylketonuria. 
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the risk of cardiovascular disease and hyperlipidaemia [19–21]. Due to 
pegvaliase being a treatment for late adolescent and adult patients with 
PKU monitoring of blood pressure, insulin resistance and lipid profile is 
recommended [22]. In addition, lifestyle and quality of life (QoL) 
questionnaires, such as the PKU-QoL [23,24], may be valuable to 
examine healthy or unhealthy changes in lifestyle and the overall impact 
of pegvaliase on the physical, emotional and social aspects of PKU 
patients. 
3.2.2. Titration and dose optimisation phase 
As indicated by the US and EU pegvaliase prescription labels, blood 
Phe should be assessed monthly during titration and dosing optimisation 
phases [12,13]. However, the consensus group suggests more frequent 
blood Phe monitoring upon the metabolic team's discretion. Centres 
with a more frequent follow-up protocol in place before adoption of 
pegvaliase, may either reconsider or continue their blood Phe moni-
toring frequency when offering pegvaliase, reflecting the patients' in-
dividual needs and support required. According to the EU pegvaliase 
prescription label, it is recommended to monitor blood Phe levels every 
two weeks in the event of low blood Phe (LBP; i.e., <30 μmol/L) [13]. 
The clinical trials have shown that prolonged periods of LBP may occur 
but the implications are unclear, thus requiring close monitoring of 
blood Phe levels to understand if LBP is related to any side effects [14]. 
Generally, the consensus group would advocate more frequent blood 
Phe monitoring than indicated in the prescription labels when this is 
clinically indicated. During the titration and dosing optimisation phase, 
nutritional intake should ideally be assessed with each blood Phe mea-
surement, using a tool of the dietitian's choice (Table 2). 
3.2.3. Maintenance phase 
Once the dietary treatment is relaxed (as described in section 3.3.2.) 
during the pegvaliase maintenance phase, patient evaluation every 6 
months in clinic to assess adherence and treatment outcomes is recom-
mended. At minimum, blood Phe should be monitored monthly, as per 
EU prescription label [13]. Blood Phe may be assessed more frequently 
upon the metabolic team's discretion, e.g., during periods when protein 
intake and/or pegvaliase dose are adjusted. The frequency of nutritional 
intake assessments may be decreased to once every 6 months together 
with the assessment of anthropometric parameters. If resources are 
available, micronutrient, amino acid and body composition analyses can 
be performed annually or on a more regular basis if necessary, partic-
ularly when managing comorbidities [20,21]. In general, all nutritional 
status assessments should be performed more often if there are any 
clinical concerns or if the treatment centre already follows a stricter 
protocol, assuming this will not cause an excessive burden for the 
patient. 
3.3. Treatment goals of pegvaliase 
3.3.1. Blood Phe target range 
Longo et al., described that it is feasible for patients on pegvaliase to 
maintain blood Phe concentrations below the usual lower target range of 
120 μmol/L and within the physiological range of 31–120 μmol/L for 
healthy adults, when taking a normal protein intake without protein 
substitute [14]. It was stressed that it is still important to avoid persis-
tent LBP or hypophenylalaninemia (<30 μmol/L). This recommendation 
was constructed from expert opinion and data that was collected during 
the pegvaliase clinical trial programme spanning over a decade, 
demonstrating that approximately 50% of patients were able to achieve 
blood Phe levels ≤120 μmol/L after 24 months of treatment [11,14]. 
The experts in our group who had personal experience of using pegva-
liase with adults with PKU supported and agreed with the recommen-
dation of Longo et al. [14]. However, some experts in our group needed 
further research with 24-h blood Phe profiling data before recom-
mending a lower blood Phe target of 31–120 μmol/L. They suggest, data 
are needed to assess the diurnal fluctuations and variations in blood Phe, 
ensuring that blood Phe concentrations can be maintained within the 
physiological range in patients who are able to normalise their diet with 
Fig. 1. Consensus group recommendations for adjustment of diet and protein intake during treatment with pegvaliase. The dietary reference intake (DRI) is defined 
as 0.8 g of protein/kg/day from a mix of animal and plant sources, excluding protein substitute supplementation. 
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pegvaliase. As a consequence, we have made no recommendation on the 
lower blood Phe target. Nevertheless, future guidance will be provided 
when additional studies and real-world experience address the amino 
acid profile, bone mineral density and growth outcomes of pegvaliase- 
treated patients achieving long-term blood Phe concentrations be-
tween 31 and 120 μmol/L while being on a normal diet. For the upper 
blood Phe target, the majority of the experts recommended targeting 
concentrations below 240–360 μmol/L. Although there is no published 
evidence in adults, recent data suggest that blood Phe concentrations 
below 240 μmol/L may improve neurocognition in children/adolescents 
with PKU [25,26]. 
3.3.2. Normalisation of diet 
3.3.2.1. Recommended protein intake. The consensus group defined a 
normal protein intake as at least 0.8 g of protein/kg/day from a mix of 
animal and plant sources, without any supplementation from protein 
substitutes, while ensuring that all nutrient requirements are met. This 
protein intake provides the recommended intake of protein defined by 
the World Health Organization [27] and should be sustained over time 
with the maintenance of adequate clinical and biochemical nutritional 
status. The dietitian is essential to ensure that these recommendations 
are met. Additionally, the dietitian should advise patients to eat high- 
quality biological protein, which may be challenging for patients who 
have not been used to eating these foods prior to treatment with peg-
valiase. For patients with PKU on a vegan diet, the protein intake should 
be, in general, 20% more (1 g of protein/kg/day), due to the intake of 
potentially lower quality protein. Currently, there is insufficient 
knowledge to make a recommendation on the upper limit for protein 
intake, especially in patients with high body mass index (BMI). The di-
etitian's primary focus should be on increasing diet quality and 
concomitantly prevent any increase in body weight that results in the 
onset or worsening of overweight or obesity. Although no robust evi-
dence exists demonstrating the real causes of overweight in PKU, 
increasing diet quality of patients with PKU should be viewed as an 
opportunity to optimise body composition as well as gut microbiota, 
with increasing evidence indicating this is unbalanced in dietary-treated 
patients with PKU [28,29]. A healthy diet with regular physical exercise 
should always be emphasised, as previously suggested [19]. 
3.3.2.2. Adjustment of diet and protein intake during treatment with 
pegvaliase. The dietitian should counsel that patients maintain a 
consistent diet and protein intake during the introduction and titration 
of pegvaliase to determine treatment response [14]. In the pegvaliase 
clinical trial protocols, patients maintained their natural and medical 
protein intake within ±10% from baseline [11]. As this is not a realistic 
goal in clinical practice, the consensus group defined a consistent diet as 
follows: “The patient's protein intake, dietary pattern and lifestyle 
should remain approximately the same as before pegvaliase initiation” 
(Fig. 1). During the pegvaliase dose optimisation phase, it is recom-
mended to increase natural protein intake when blood Phe concentra-
tions are between 30 and 240 μmol/L in patients on a Phe-restricted diet. 
Natural protein intake should be increased following two low blood Phe 
measurements (Fig. 1). Natural protein should be increased in in-
crements of 10–20 g, considering the comfort level of the patient 
(Fig. 1). Patients on a Phe-restricted diet may be hesitant about relaxing 
natural protein intake by large increments and may encounter several 
challenges when increasing natural protein intake, e.g., taste, texture 
and smell of foods, cost, cooking, choosing non-nutritious foods or poor- 
quality protein. Therefore, it is necessary to review the patients' ex-
pectations, offering them education and counselling to ensure any 
individualised plan of introducing protein is implemented. Also, when 
increasing the intake of natural protein, the protein equivalent from 
protein substitute should be assessed and reduced if necessary (Fig. 1). 
For patients on a regular, protein-containing diet prior to starting 
pegvaliase, protein adjustments will be dependent on the baseline 
nutritional status of the individual patient and usual protein intake. If 
the patient does not meet the recommended protein intake (i.e., 0.8 g of 
protein/kg/day from a mix of animal and plant sources, excluding 
protein substitute supplementation), natural protein intake can be 
increased. Patients should be encouraged to eat high-quality protein to 
ensure balanced nutrition. When the nutritional needs are met and blood 
Phe remains within the treatment target range, no adjustments to the 
dietary protein intake should be made in the first phase of pegvaliase 
treatment (Fig. 1). In case natural protein intake is above the DRI for 
protein, dose reduction can be considered if the patient is well- 
controlled on pegvaliase (Fig. 1). In the event of LBP, patients should 
be advised to increase natural protein intake. When diet is normalised, 
Table 3 
Summary of the dietitian road map recommendations developed by the 
consensus group.  
Topic Recommendation(s) by the consensus group 
Multidisciplinary team The core treatment team should comprise a physician, 
dietitian/nutritionist and a nurse. If resources are 
available, also a psychologist/counsellor (highly 
recommended), social worker, home support worker 




- Blood Phe concentrations, anthropometrics and 
nutritional intake were identified as minimally 
required for follow-up 
- Blood Phe concentrations should be assessed 
monthly (or every 2 weeks in case of low blood Phe, 
<30 μmol/L), but may be monitored more frequently 
upon the metabolic team's discretion, e.g., when 
changing protein intake or pegvaliase dose 
- Nutritional intake is ideally monitored with each 
blood Phe measurement, preferably using a food 
frequency questionnaire in combination with 24-h 
recall or 3-day food records 
- Practical recommendations for additional 
nutritional assessments can be found in Table 2 
Treatment goals of 
pegvaliase 
- Pegvaliase should aim to maintain blood Phe levels 
below 240 μmol/L but more evidence on the safety of 
achieving physiological blood Phe levels will need to 
be collected before making any recommendation on 
the lower limit of the blood Phe target range 
- A normalised diet: at least 0.8 g of protein/kg/day 
(DRI for protein intake) from a mix of animal and 
plant sources, without any supplementation from 
protein substitutes, while ensuring that all nutrient 
requirements are met 
- Additional goals: improvements in neurocognition 
and (neuro)psychological outcomes, quality of life 
and emotional well-being 
Adjustment of diet and 
protein intake 
- When starting pegvaliase, the patient should be on a 
consistent diet, defined as: “The patient's protein 
intake, dietary pattern and lifestyle should remain 
approximately the same as before pegvaliase 
initiation” 
- An increase in natural protein intake can be 
considered when blood Phe concentrations are below 
240 μmol/L but should be individualised 
- Natural protein should be increased by increments of 
10–20 g per day 
- If the patient is taking protein substitutes, these 
should be reduced proportionally if this is possible, 
once natural protein intake is increased 
- Protein intake of vegan patients should be generally 
20% more, but nutritional status needs to be 
calculated on an individual basis 
- In obese patients, care should be focussed on diet 
and exercise to reduce weight 
Education Patient education before and during treatment with 
pegvaliase is crucial, with a focus on nutritional 
intake and correct use of pegvaliase 
DRI: dietary reference intake; Phe: phenylalanine. 
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dose reduction should be considered. Regardless of the dietary or dose 
adjustments, blood Phe concentrations should be monitored closely to 
evaluate the impact of changes in natural protein intake or dose on the 
outcomes of pegvaliase. 
3.3.3. Additional treatment goals 
Additional treatment goals of pegvaliase are improvements in neu-
rocognition and (neuro)psychological outcomes, QoL and emotional 
well-being, together with the minimisation of comorbidities, such as 
obesity and metabolic syndrome [19]. These additional goals emphasise 
the importance of a multidisciplinary team (Table 1), including a psy-
chologist/counsellor, in the management of patients with PKU on 
pegvaliase. 
3.4. Education 
Education of patients before treatment with pegvaliase and during 
the transition to a normalised diet is crucial to ensure correct use of 
pegvaliase and appropriate dietary management. One-on-one counsel-
ling should continue to be the mainstay but can be complemented with 
additional educational tools to inform and support patients with PKU 
before and during treatment with pegvaliase. Printed educational ma-
terials, such as information leaflets/handouts, remain important but 
may not be sufficient to convey the message, as patients are not always 
reading or understanding these. Other tools enabling patient education 
may include instructional videos, workshops and mobile applications for 
(self-)monitoring diet and pegvaliase injections [30]. 
Dietitians should be educated on the nutritional challenges of pa-
tients treated with pegvaliase. Although the interaction between dieti-
tian and patient may be reduced after diet normalisation from once 
monthly to semi-annually, it remains important to maintain this central 
point of contact for follow-up of comorbidities and long-term diet 
ensuring patients continue to eat an adequate diet meeting the nutri-
tional needs of each patient and for re-education of pegvaliase-treated 
patients. Moreover, dietary guidance is essential in patients who may 
discontinue pegvaliase, e.g., adverse events. This includes counselling 
the patient on how to return to diet when pegvaliase is not an option. 
Furthermore, Longo et al. recommend discontinuation of pegvaliase use 
at least 4 weeks prior to a planned pregnancy [14]. Therefore, nutrition 
counselling is essential to avoid hyperphenylalaninemia throughout 
(pre)pregnancy, after which rechallenge of pegvaliase can be success-
fully implemented [31]. 
4. Conclusions 
This practical road map was developed to provide initial guidance for 
dietitians, who have an essential role in the management of patients on 
pegvaliase. The recommendations were developed by dietitians who had 
previously treated adult PKU patients with pegvaliase together with 
insights from dietitians and one paediatrician who have experience in 
treating PKU patients in Europe. Because only one EU dietitian had 
previous experience with using pegvaliase, guidance on the clinical 
approach was mainly adapted from US experience. Combining the out-
comes of a face-to-face data-review meeting and a virtual consolidation 
meeting, consensus recommendations were formed among the PKU ex-
perts on the composition of the core pegvaliase treatment team, the 
nutritional evaluation and management of patients on pegvaliase, 
treatment goals and on education of dietitians and patients using peg-
valiase. A summary of the dietitian road map recommendations can be 
found in Table 3. 
As these recommendations are based on expert opinion and available 
literature only, they are intended to provide initial recommendations to 
dietitians. In the future, these dietary recommendations will be updated 
based on additional evidence and increasing experience from the 
metabolic teams. 
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